Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

347.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 Next >
Vertex to Announce Third Quarter 2022 Financial Results on October 27
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Shares Higher On Optimism About CRISPR Partnership
Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments. 
Via MarketBeat
Exposures Product Safety
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Appoints Jonathan Biller as Chief Legal Officer
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative... 
Via TheNewswire.com
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Reports Second Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Advances VX-548 in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce Second Quarter 2022 Financial Results on August 4
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Vertex Pharmaceuticals Incorporated Investors with Losses to Inquire About Class Action Investigation – VRTX
From The Rosen Law Firm, P.A.
Via Business Wire
Suketu Upadhyay Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
From Vertex Pharmaceuticals
Via Business Wire
Vertex Reports First Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce First Quarter 2022 Financial Results on May 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.